No Data Yet
The U.S. Securities and Exchange Commission has stopped the approval of exchange-traded funds offering more than 2x daily leverage, citing non-compliance with derivatives regulations. This impacts product issuers and signals a stricter stance on complex retail-focused products.
Alnylam Pharmaceuticals (ALNY) will be added to the Nasdaq-100 Index on December 22, 2025. This significant event provides a strong institutional buying catalyst, directly countering recent market concerns about near-term growth headwinds and a lack of late-stage pipeline news.
Portfolio
